Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193152 · ClinicalTrials.gov registry record · Phase 2
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02193152 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 16 participants.
The verdict
NCT02193152, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how participants with advanced non-small cell lung cancer (NSCLC) that have certain abnormalities in the pazopanib target genes respond to pazopanib treatment.
Interventions
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-04-27 |
| Est. Completion | 2019-12-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02193152
The ClinicalTrials.gov registry entry for NCT02193152 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib is the first listed.
NCT02193152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02193152 about?
NCT02193152 is a clinical study titled "Pazopanib in Molecularly Selected Patients With Advanced NSCLC". The purpose of this study is to evaluate how participants with advanced non-small cell lung cancer (NSCLC) that have certain abnormalities in the pazopanib target genes respond to pazopanib treatment.
What is the current status of trial NCT02193152?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-04-27. Estimated completion is 2019-12-24.
What interventions are being tested in trial NCT02193152?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT02193152?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.